Background

Background

The manufacturer of panitumumab (Amgen) was invited to submit evidence for this single technology appraisal of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer.

In July 2011, Amgen informed NICE that it would not be making an evidence submission. Amgen stated that, taking into account approaches previously used by NICE to appraising drugs for the treatment of colorectal cancer, there was not sufficient evidence to robustly estimate the cost effectiveness of panitumumab for this indication.

NICE has therefore terminated this single technology appraisal.

  • National Institute for Health and Care Excellence (NICE)